Minerva S.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Fernando Galletti de Queiroz
- Full Time Employees
- 40,000
- Sector
- Distribution services
- Industry
- Food distributors
- Address
- Avenida Antônio Manço Bernardes s/nº Barretos SP Brazil 14781-545
- IPO Date
- Jul 24, 2007
- Website
- minervafoods.com
- Similar Companies
- Business
- Minerva S.A. (BEEF3.SA) is a leading South American exporter of fresh beef, live cattle, and by-products, operating 25 slaughterhouses across Brazil (10 units), Paraguay (five), Uruguay (three), Argentina (five), and Colombia (two) with a combined daily cattle slaughter capacity of 26,380 head; it also maintains meat processing plants including Minerva Fine Foods in Brazil for cooked frozen products and Swift Argentina plants for beef, pork, and poultry processing with capacities of 162 and 55 tons per day respectively, alongside offerings of chilled, frozen, and processed meats such as hormone-free pasture-raised lamb under the Sovereign brand and convenient ready-to-eat products under the PUL brand, as well as veal cuts including tenderloin, chops, shank, and cutlets; the company exports to over 100 countries across five continents via 15 sales offices and 14 distribution centers (nine in Brazil), trades in electric power, food products, carbon credits, third-party brands like Swift, and animal by-products including meat/bone meal, blood, and tallow, while breeding and selling live cattle, lambs, pigs, and other animals. Founded by the Vilela de Queiroz family with cattle raising and logistics in 1957 and industrial operations beginning in 1992 upon acquiring its first slaughterhouse in Barretos, São Paulo—its current headquarters—Minerva operates primarily in the beef industry with segments in live cattle exports and other proteins, targeting wholesale, retail, and foodservice customers globally including major markets in China, North America, Europe, the Middle East, Asia, Africa, and the Americas. In October 2024, the company completed its largest-ever acquisition for BRL 7.5 billion, purchasing 13 cattle and sheep slaughter/deboning plants plus a distribution center in Brazil from Marfrig Global Foods following CADE approval, expanding its Brazilian slaughter capacity to 22,336 head per day across 21 plants and reinforcing its position as South America's top beef exporter with enhanced synergies, market arbitrage, and access to key international destinations; this follows prior expansions like the 2017 JBS Mercosur acquisition and includes ongoing initiatives such as J.P. Morgan Payments partnership for working capital optimization, MyCarbon subsidiary advancements in carbon credits across 145,700 hectares, and investment in The EVERY Company's precision fermentation for egg proteins.
Company News
Minerva S.A. (OTCMKTS:MRVSY) Short Interest Update
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 57,2 BILLION FOR THE PAST 12 MONTHS
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Minerva Launches AI Platform for Consumer Marketing with $20M from The General Partnership, 8VC, Lingotto Innovation, Topology Ventures and NBA Investments, Alongside OpenAI Collaboration
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva S.A. (MRVSY) Q1 2026 Earnings Call Transcript
MINERVA FOODS REPORTS R$ 13.4 BILLION IN NET REVENUE IN THE FIRST QUARTER OF 2026
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Minerva Announces Leadership Transition
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva S.A. (MRVSY) Q4 2025 Earnings Call Transcript
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 54.8 BILLION IN 2025
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 54.8 BILLION IN 2025
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026